Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and debilitating disease with no molecular diagnostics and no treatment options. To identify potential markers of this illness, we profiled 48 patients and 52 controls for standard laboratory tests, plasma metabolomics, blood i...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2020-11, Vol.10 (1), p.19933-19933, Article 19933
Main Authors: Kitami, Toshimori, Fukuda, Sanae, Kato, Tamotsu, Yamaguti, Kouzi, Nakatomi, Yasuhito, Yamano, Emi, Kataoka, Yosky, Mizuno, Kei, Tsuboi, Yuuri, Kogo, Yasushi, Suzuki, Harukazu, Itoh, Masayoshi, Morioka, Masaki Suimye, Kawaji, Hideya, Koseki, Haruhiko, Kikuchi, Jun, Hayashizaki, Yoshihide, Ohno, Hiroshi, Kuratsune, Hirohiko, Watanabe, Yasuyoshi
Format: Article
Language:English
Subjects:
692/1807/1486
692/53/2421
Biomarkers - analysis
Case-Control Studies
Chronic fatigue syndrome
Cognitive ability
Cohort Studies
Encephalomyelitis
Fatigue
Fatigue Syndrome, Chronic - epidemiology
Fatigue Syndrome, Chronic - genetics
Fatigue Syndrome, Chronic - metabolism
Fatigue Syndrome, Chronic - pathology
Fecal microflora
Feces - microbiology
Humanities and Social Sciences
Humans
Japan - epidemiology
Laboratory tests
Lipoproteins
Metabolome
Metabolomics
Microbiomes
Microbiota
Monocytes
multidisciplinary
Phenotyping
Science
Science (multidisciplinary)
Sleep
Transcriptome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and debilitating disease with no molecular diagnostics and no treatment options. To identify potential markers of this illness, we profiled 48 patients and 52 controls for standard laboratory tests, plasma metabolomics, blood immuno-phenotyping and transcriptomics, and fecal microbiome analysis. Here, we identified a set of 26 potential molecular markers that distinguished ME/CFS patients from healthy controls. Monocyte number, microbiome abundance, and lipoprotein profiles appeared to be the most informative markers. When we correlated these molecular changes to sleep and cognitive measurements of fatigue, we found that lipoprotein and microbiome profiles most closely correlated with sleep disruption while a different set of markers correlated with a cognitive parameter. Sleep, lipoprotein, and microbiome changes occur early during the course of illness suggesting that these markers can be examined in a larger cohort for potential biomarker application. Our study points to a cluster of sleep-related molecular changes as a prominent feature of ME/CFS in our Japanese cohort.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-77105-y